PolyPeptide Group

PolyPeptide Group is a Contract Development & Manufacturing Organization (CDMO) that specializes in peptide- and oligonucleotide-based active pharmaceutical ingredients (APIs). Founded in 1952 in Malmö, Sweden, the company has developed a global presence with six GMP-certified facilities in Europe, the U.S., and India. It is publicly traded on the SIX Swiss Exchange under the ticker symbol PPGN. The company provides comprehensive services, including custom API development, clinical and commercial manufacturing, and regulatory support. PolyPeptide has produced over 1,000 GMP-compliant peptides and expanded into oligonucleotides in 2021 to meet the rising demand for RNA-based therapies. Its product offerings include therapeutic peptides for various medical applications, oligonucleotides, and cosmetic peptides for skincare. PolyPeptide focuses on supporting pharmaceutical and biotech companies, particularly in the areas of metabolic diseases and personalized medicine.